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BioprecursorAbstract In an attempt to minimize the ulcerogenic potential and associated gastro-intestinal tox-
icity of bioprecursor fenbufen and its active metabolite biphenyl acetic acid, carrier-linked chimeric
derivatives of the latter were designed and synthesized using amino acids as the promoities. DCC
coupling method was used for the synthesis of these amides. The chimeras were characterized by
IR and 1H NMR. Pharmacological investigations were carried out in animal models for analgesic,
anti-inﬂammatory, anti-arthritic and ulcerogenic activities. The chimeras exhibited high gastro-
sparing effect; quick onset and longer duration of analgesia; enhanced/prolonged anti-inﬂammatory
activity and better anti-arthritic effect than fenbufen or biphenyl acetic acid. These derivatives could
be useful as a chronotherapy for rheumatoid arthritis due to their prolonged analgesic and anti-
inﬂammatory effects.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is an autoimmune inﬂammatory
disorder, affecting about 1% of the world’s population. RAcauses irreversible destruction of the cartilage, tendon, and
bone that comprise synovial joints (Burrage et al., 2006). Non-
steroidal anti-inﬂammatory drugs (NSAIDs) form the main-
stay treatment of RA. Clinical use of most of the available
acidic NSAIDs is strongly limited by their GI side effects
which range in both severity and frequency from relatively
mild to severe gastrointestinal toxicities (Gad, 2011). The latter
are more serious and potentially life threatening, such as GI
ulceration and hemorrhage (Laine, 2001). Fenbufen is a phe-
nylalkanoic acid class NSAID, used in the treatment of rheu-
matic and other musculoskeletal disorders (Aronson, 2010;
Brogden et al., 1981). It is metabolized into four major metab-
olites: c-hydroxy[1,10-biphenyl]-4-butanoic acid (I), [1,10-
biphenyl]-4-acetic acid (II), 40-hydroxy[1,10-biphenyl]-4-acetic
S212 S. Dhaneshwar et al.acid (III), and c,40-dihydroxy[1,10-biphenyl]-4-butanoic acid
(IV). Metabolites III and IV are inactive while metabolites I
and II are biologically active that circulate to plasma (Brogden
et al., 1981). The major metabolite, biphenylacetic acid (BPA;
metabolite II); is a potent prostaglandin synthetase inhibitor
while the literature reports that fenbufen has no inhibitory ef-
fect on cyclooxygenase. Therefore fenbufen ﬁts into the con-
ventional deﬁnition of bioprecursor prodrug. The major
contributor to the GI injury caused by the oral administration
of fenbufen is a direct local irritant effect of free carboxylic
group of fenbufen and BPA (Kerwar, 1983). The characteristic
drawback of bioprecursors is their susceptibility to more than
one metabolic enzyme, some of which might inactivate them
while others might biotransform them into active metabolites
(Wermuth, 2008). As the enzymatic set up of every individual
is different, this scenario of multiple metabolic pathways leads
to high incidences of inter-subject variation and poor bioavail-
ability attributed to inactive metabolites. Conversion of a bio-
precursor into a carrier-linked, chimeric derivative might
improve the inter-subject variation and bioavailability. Several
attempts have been tried for enhancing its action and/or min-
imization of its ulcerogenic potential by various research
groups. Conjugates of BPA with one of the primary hydroxyl
groups of a, b and c-cyclodextrins (CyDs) through an ester or
amide linkage for colon-speciﬁc delivery have been reported
(Minami et al., 1998). Mutual hydrazide prodrugs of probene-
cid and diclofenac with biphenylacetic acid with lower ulcerog-
enicity and increased anti-inﬂammatory effect have been
reported (Sharma and Khan, 2003). Sharma et al. (2004,
2010) have also reported a number of potential mutual pro-
drugs of BPA by the attachment of several phytophenols/alco-
hol as promoieties through ester linkage, directly as well as
through spacers, with the objective of obtaining safer NSAIDs
devoid of ulcerogenic side effects. Khan et al. (2006) have re-
ported glyceride prodrugs of BPA to reduce its gastrointestinal
toxicity. A gastro-sparing prodrug of 4-biphenylacetic acid and
quercetin tetramethyl ether has been reported by Madhukar
et al. (2010) which was devoid of any ulcerogenic side effects.
In one of our preliminary studies we investigated the poten-
tial of L-tyrosine conjugate of BPA to minimize its ulcerogenic
effect (Dhaneshwar and Sharma, 2012), the positive results of
which motivated us to explore the usefulness of L-tryptophan
and L-glutamine as promoities in the design of gastro-sparing
chimeric derivatives of BPA. Also we did not ﬁnd any other re-
ports of BPA-amino acid conjugates in the literature. The ami-
no acids L-tryptophan and L-glutamine were chosen for linking
them covalently with BPA due to their inherent anti-inﬂamma-
tory activity and wound healing effects. Madan and Khanna
(1978) have reported that L-tryptophan reduces the pain of
arthritis (Dhaneshwar et al., 2011). L-Tryptophan being the
precursor of serotonine, results in increased serotonine levels
which have an effect on increasing pain tolerance, especially
for chronic pain caused from arthritis and lower back prob-
lems (Fth, 2012). Glutamine metabolism provides precursors
for the synthesis of glutathione, an antioxidant, which protects
the body from oxidative stress (Soledad et al., 2005). Gluta-
mine also acts as an immune-nutrient and helps in promoting
wound healing (Nora and Fatma, 2011). Based on these ﬁnd-
ings, we hypothesized that conjugation of these amino acids
with BPA might potentiate its effect against inﬂammation in
RA with additional gastro-sparing effect due to temporary
masking of carboxylic group of BPA which is thought to bepartially responsible for local upper GIT irritation. It was fur-
ther rationalized that co-administration of BPA and amino
acids in the form of single chemical entity as chimeras with
complementary activities (anti-inﬂammatory/antioxidant
activities) might prove to be potentially advantageous.
2. Experimental
Biphenylacetic acid (BPA) and dicyclohexyl carbodimide
(DCC) were purchased from Sigma–Aldrich, Germany. Amino
acids and dimethylamino pyridine (DMAP) were purchased
from Loba Chemie, Mumbai, India. Fenbufen was purchased
from Shanghai AoBo Bio-pharmaceutical Technology Co.,
Ltd., Shanghai, China, which was used as a standard for phar-
macological studies. All other chemicals used in the synthesis
were of A.R. grade and those of the synthetic grade were puri-
ﬁed prior to use. 1H NMR spectra of the derivatives were re-
corded in DMSO-d6 using
1H NMR Varian Mercury
300 MHz with a super conducting magnet using TMS as inter-
nal standard at the Department of Chemistry, University of
Pune, Pune. Chemical shift values are reported in ppm downﬁeld
on d scale. The IR spectra of the synthesized compounds were re-
corded on JASCO, V-530 FTIR in potassium bromide (anhy-
drous IR grade). The absorbance maxima (kmax) of synthesized
prodrugs were determined on JASCO V530, UV–Visible dou-
ble-beam spectrophotometer. Partition coefﬁcient was deter-
mined in n-octanol/phosphate buffer (pH 7.4). The reactions
were monitored by TLC on pre-coated silica gel plates-60 F264
(Merck) in benzene:ethyl acetate:glacial acetic acid (2:1:0.1 v/v)
solvent system. The TLC spots were located by exposing to io-
dine vapors or UV light. Melting points were recorded on preci-
sion melting point apparatus and are uncorrected.
2.1. Synthesis of chimeric derivatives of BPA with amino acids
Amino acids were esteriﬁed to methyl ester hydrochloride by
Ronald’s reported method. These were treated with triethyl-
amine to release free amino acid methyl esters which were then
coupled with BPA using DCC. The scheme of synthesis is illus-
trated in Fig. 1.
2.1.1. Synthesis of amino acid methyl ester hydrochloride
(Ronalds et al., 1969; Dhaneshwar et al., 2011)
Freshly distilled thionyl chloride (0.05 mol + 30% excess;
5 mL) was slowly added to methanol (100 mL) with cooling
and amino acid (0.1 mol) was added to it. The mixture was re-
ﬂuxed for 8 h at 60–70 C with continuous stirring on magnetic
stirrer, excess of thionyl chloride and solvent was removed un-
der reduced pressure giving the crude product. It was tritu-
rated with 2 · 20 mL portions of cold ether at 0 C until
excess of dimethyl sulﬁde was removed. The resulting solid
product was collected and dried under high vacuum to give
dried methyl ester hydrochloride of amino acid. It was recrys-
tallized from hot methanol by a slow addition of 30–40 mL of
ether, followed by cooling at 0 C. Crystals were collected the
next day and washed twice with ether:methanol mixture (5:1)
followed by pure ether and dried under vacuum.
2.1.1.1. L-Tryptophan methyl ester hydrochloride (TMEÆHCl).
% Yield: 88, mp: 202–205 C (uncorrected), Rf: 0.69 in meth-
anol:water (2:1 v/v), IR (KBr; cm1): 1748 C‚O stretching
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Figure 1 Scheme of synthesis.
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secondary amine.
2.1.1.2. L-Glutamine methyl ester hydrochloride (GMEÆHCl).
% Yield: 25, mp: 220–225 C (uncorrected), Rf: 0.7 in metha-
nol, ethyl acetate, glacial acetic acid (1:0.2:0.1 v/v), IR (KBr;
cm1): 3365, 3290 NH stretching primary amine, 2960 ali-
phatic C–H stretching, 1742 C‚O stretching ester, 1656
C‚O stretching secondary amide.
2.1.2. Conjugation of amino acid methyl esters with BPA
2.1.2.1. Synthesis of 2-(2-biphenyl-4-yl-acetylamino)-3-(1H-
indol-3-yl)-propionic acid (BP-1) (Hitoshi et al., 1995; Furniss
et al., 2005). To the suspension of TMEÆHCl (0.025 mol, 3.9 g)
in 30 mL dichloromethane, triethylamine (0.05 mol, 6.9 mL)
was added with stirring at 0 C for 30 min. The reactionmixture
was then ﬁltered and dichloromethane was distilled off to get
TME. DCC (0.01 mol, 2.063 g) was added to a solution of
BPA (0.01 mol, 2.15 g) in 50 mL of dimethylformamide
(DMF), with stirring at 0 C for 1 h. To the reaction mixture,
TME (0.0106 mol, 2.28 g) was added and stirred mechanically
at 0 C for 3 h then at room temperature for 72 h. The reaction
mixture was ﬁltered to remove the precipitated dicyclohexylureaand the ﬁltrate was washed with 1 Mhydrochloric acid (15 mL),
5% sodium bicarbonate (15 mL) and saturated solution of so-
dium chloride (10 mL) respectively. After ﬁltration, the ﬁltrate
was evaporated under reduced pressure to give crude product.
The crude product was further puriﬁed by preparative TLC
using benzene:ethyl acetate:glacial acetic acid (2:1:0.1 v/v) sol-
vent system.
BP-1: % yield: 55, mp: 140–145 C (uncorrected), Rf: 0.53,
benzene:ethyl acetate:glacial acetic acid (2:1:0.1 v/v), logP:
0.46 (n-octanol:phosphate buffer pH 7.4), kmax: 254 nm (phos-
phate buffer pH 7.4), IR (KBr; cm1): 3600 NH stretching in-
dole; 3400 OH stretching COOH; 3319 NH stretching
secondary amide; 3029 aromatic CH stretching; 1724 C‚O
stretching COOH; 1650 C‚O stretching amide; 1578 NH
bending secondary amide; 1402 CH2 bending.
1H NMR
(DMSO-d6,): d 11.05 [s, 2H] NH indole and COOH, d 7.95
[s, 1H] NH amide, d 6.96–7.64 [m, 13 H] aromatic and indole
CH, d 4.03 [t, 1H] CH methine, d 3.61 [s, 2H] CH methylene, d
3.23 [d, 2H] CH2 methylene.
2.1.2.2. Synthesis of 2-(2-biphenyl-4-yl- acetylamino)-4-car-
bamoyl-butyric acid (BP-2) (Hitoshi et al., 1995; Furniss et al.,
2005; Marieta, 1999). To the suspension of GMEÆHCl
Table 1 Analgesic activity by hot plate-induced hyperalgesia.
Group Dose (mg/kg) Latency period (s)
0 min 30 min 60 min 90 min 120 min 180 min
BPA 12 12.1 ± 0.02 12.1 ± 0.04 24.9 * ± 0.03 26.5** ± 0.04 17.4 ± 0.05 16.3 ± 0.04
FEN 15 12.1 ± 0.05 19 ± 0.09 13.6 ± 0.06 14.1 ± 0.06 21.6** ± 0.08 13.5 ± 0.09
BP-1 22.4 15.3 ± 0.05 13.6 ± 0.07 26.6** ± 0.08 28.3** ± 0.03 39.9*** ± 0.06 6.7 ± 0.07
BP-2 19.24 8.9 ± 0.07 11.1 ± 0.09 22** ± 0.03 25** ± 0.06 20** ± 0.07 25.5** ± 0.06
TP 11.5 8 ± 008 14.9 ± 0.05 24.7** ± 0.06 11.5 ± 0.07 7.1 ± 0.06 15 ± 0.09
GLU 8.27 12.5 ± 0.07 8.6 ± 0.08 23.3** ± 0.05 11.8 ± 0.04 18.1 ± 0.08 4.7 ± 0.09
PMT 23.55 13.6 ± 0.07 16 ± 0.08 23.9** ± 0.06 14.9 ± 0.05 11.4 ± 0.07 15 ± 0.09
PMG 20.27 13.4 ± 0.08 15.2 ± 0.06 11.1 ± 0.07 18.4* ± 0.08 17.1 ± 0.02 15.5 ± 0.06
BPA: biphenyl acetic acid, FEN: fenbufen, BP-1: chimeric derivative of BPA with L-tryptophan, BP-2: chimeric derivative of BPA with
L-glutamine, TP: L-tryptophan, GLU: L-glutamine, PMT: physical mixture of BPA with L-tryptophan, PMG: physical mixture of BPA with
L-glutamine.
* Average of six readings ±SEM, P< 0.05.
** Average of six readings ±SEM, P< 0.01.
*** Average of six readings ±SEM, P< 0.001.
Table 2 Change in paw volume in carrageenan-induced rat hind paw edema.
Dose in (mg/kg) Time (h)
1 h 3 h 4 h 6 h 8 h 24 h
CC 1% carrageenan 1.7 ± 0.02 2.94 ± 0.06 2.94 ± 0.08 3.18 ± 0.06 3.8 ± 0.07 4.6 ± 0.09
BPA 12 1.3 ± 0.04 2.06 ± 0.07 2.05 ± 0.06 2.11 ± 0.03 2.41 ± 0.02 1.79 ± 0.06
FEN 15 1.42 ± 0.06 2.36 ± 0.04 2.36 ± 0.07 2.39 ± 0.09 2.76 ± 0.04 1.87 ± 0.02
BP-1 22.4 1.28 ± 0.07 1.62 ± 0.08 1.62 ± 0.04 1.66 ± 0.08 1.68 ± 0.06 1.2 ± 0.04
BP-2 19.24 1.27 ± 0.04 1.98 ± 0.05 1.98 ± 0.05 2.09 ± 0.06 1.89 ± 0.08 1.73 ± 0.06
TP 11.22 1.45 ± 0.08 1.34 ± 0.07 1.34 ± 0.07 1.89 ± 0.04 2.23 ± 0.06 2.1 ± 0.05
GLU 8.47 1.59 ± 0.05 2.6 ± 0.06 2.6 ± 0.07 2.52 ± 0.06 2.86 ± 0.07 3.22 ± 0.07
PMT 23.55 1.37 ± 0.06 1.93 ± 0.08 1.93 ± 0.06 1.83 ± 0.02 1.92 ± 0.05 1.84 ± 0.08
PMG 20.27 1.4 ± 0.03 2.38 ± 0.04 2.38 ± 0.02 2.42 ± 0.07 2.62 ± 0.04 2.31 ± 0.09
CC: Carrageenan control, BPA: biphenyl acetic acid, FEN: fenbufen, BP-1: chimeric derivative of BPA with L-tryptophan, BP-2: chimeric
derivative of BPA with L-glutamine, TP: L-tryptophan, GLU: L-glutamine, PMT: physical mixture of BPA with L-tryptophan, PMG: physical
mixture of BPA with L-glutamine.
Table 3 Percent inhibition of edema in carrageenan-induced rat hind paw edema.
Dose in (mg/kg) Time in hour/Percent inhibition of edema
1 h, % 3 h, % 4 h, % 6 h, % 8 h, % 24 h, %
BPA 12 19.6 21.4 30.0 34.1 36.6 61.0**
FEN 15 16.5 18.6 19.7 24.8 27.4 59.3**
BP-1 22.4 24.7 33.3 44.9 47.7 55.8 74.0***
BP-2 19.24 25.2 27.6 32.7 34.3 54.5 62.4**
TP 11.22 14.7 48.6 54.3 40.5 41.2 54.3*
GLU 8.47 6.0 9.5 11.6 20.7 24.7 30.0
PMT 23.55 19.4 22.8 34.4 42.2 49.4 60.0**
PMG 20.27 17.6 19.5 20.1 23.9 31.2 50.0*
BPA: biphenyl acetic acid, FEN: fenbufen, BP-1: chimeric derivative of BPA with L-tryptophan, BP-2: chimeric derivative of BPA with L-
glutamine, TP: L-tryptophan, GLU: L-glutamine, PMT: physical mixture of BPA with L-tryptophan PMG: physical mixture of BPA with L-
glutamine.
* Average of six readings ±SEM, P< 0.05.
** Average of six readings ±SEM, P< 0.01.
*** Average of six readings ±SEM, P< 0.001.
S214 S. Dhaneshwar et al.(0.025 mol, 4.9 g) in 30 mL dichloromethane, triethylamine
(0.05 mol, 6.9 mL) was added with stirring at 0 C for 2 h.
The reaction mixture was then ﬁltered and dichloromethane
was distilled off to get GME. DMAP (0.0007 mol, 0.085 g)and DCC (0.01 mol, 2.063 g) were added to a solution of
BPA (0.01 mol, 2.15 g) in 50 mL of DMF with stirring at
0 C for 3 h. To the reaction mixture, GME (0.011 mol,
1.80 g) was added and stirred mechanically at 0 C for 3 h
Table 4 Change in paw volume and % inhibition of edema in Freund’s adjuvant-induced arthritis.
Dose (mg/kg) Paw volume Chan e in paw volume % Inhibition of edema
1 day 4 day 7 day 13 day 18 day 21 day 18 da 21 day 18 day 21 day
HC 1 % CMC 2.26 ± 0.06 2.29 ± 0.02 2.34 ± 0.04 2.39 ± 0.02 2.43 ± 0.03 2.26 ± 0.06 0.17 0.25 – –
AC 0.1 ml CFA 2.72 ± 0.05 8.03 ± 0.08 5.28 ± 0.06 5.93 ± 0.07 5.81 ± 0.08 2.72 ± 0.05 3.81 4.01 – –
BPA 12 2.82 ± 0.03 5.41 ± 0.06 5.22 ± 0.02 5.01 ± 0.07 4.61 ± 0.09 2.82 ± 0.03 1.8 1.38*** 52.75 66.0
FEN 15 2.19 ± 0.07 5.75 ± 0.06 4.92 ± 0.05 4.57 ± 0.03 4.31 ± 0.05 2.19 ± 0.07 2.12 1.89** 44.35 53.0
BP-1 22.4 2.85 ± 0.04 5.9 ± 0.02 5.19 ± 0.06 5.01 ± 0.07 4.25 ± 0.07 2.85 ± 0.04 1.4 1.16*** 63.25 71.0
BP-2 19.24 2.56 ± 0.06 5.77 ± 0.07 5.35 ± 0.05 5.49 ± 0.06 4.03 ± 0.08 2.56 ± 0.06 1.47 1.21*** 61.41 70.0
TP 11.22 2.35 ± 0.02 5.04 ± 0.05 4.99 ± 0.03 5.22 ± 0.07 3.78 ± 0.08 2.35 ± 0.02 1.98 1.65 48.03 59.0
GLU 8.47 2.58 ± 0.05 6.01 ± 0.06 5.7 ± 0.04 5.06 ± 0.08 4.89 ± 0.07 2.58 ± 0.05 2.31 2.26 39.37 44.0
PMT 23.55 2.87 ± 0.03 5.24 ± 0.02 5.52 ± 0.05 5.37 ± 0.04 4.74 ± 0.06 2.87 ± 0.03 1.85 1.57** 51.44 61.0
PMG 20.27 2.67 ± 0.04 6.31 ± 0.05 5.34 ± 0.06 4.77 ± 0.08 4.58 ± 0.07 2.67 ± 0.04 1.91 1.82 49.86 55.0
HC: healthy control, AC: arthritis control, BPA: biphenyl acetic acid, FEN: fenbufen, BP-1: chimeric derivative of BPA with L-tryptophan, BP-2: chimeric derivative of BPA with L-glutamine, TP: L-
tryptophan, GLU: L-glutamine, PMT: physical mixture of BPA with L-tryptophan, PMG: physical mixture of BPA with L-glutamine.
** Average of six reading ±SEM, P< 0.01.
*** Average of six reading ±SEM, P< 0.001.
Table 5 Change in joint diameter in Freund’s adjuvant-induced arthritis.
HC AC BPA FEN BP-1 BP-2 TP GLU PMT PMG
0 day 0 0 0 0 0 0 0 0 0 0
4 day 0.07 ± 0.01 0.21 ± 0.03 0.1 ± 0.02 0.2 ± 0.04 0.19 ± 0.04 0.11 ± 0.03 0.1 ± 0. 2 0.38 ± 0.01 0.2 ± 0.01 0.3 ± 0.03
7 day 0.01 ± 0.02 0.35 ± 0.03 0.15 ± 0.04 0.15 ± 0.01 0.21 ± 0.02 0.35 ± 0.03 0.27 ± 0. 1 0.25 ± 0.02 0.24 ± 0.04 0.36 ± 0.01
10 day 0.03 ± 0.02 0.35 ± 0.01 0.2 ± 0.04 0.12 ± 0.02 0.23 ± 0.01 0.25 ± 0.01 0.21 ± 0. 4 0.2 ± 0.03 0.22 ± 0.02 0.3 ± 0.01
14 day 0.06 ± 0.01 0.31 ± 0.02 0.1 ± 0.04 0.09 ± 0.03 0.19 ± 0.04 0.13 ± 0.02 0.26 ± 0. 1 0.15 ± 0.01 0.14 ± 0.01 0.27 ± 0.04
18 day 0.04 ± 0.04 0.28 ± 0.03 0.08 ± 0.01 0.09 ± 0.01 0.06 ± 0.03 0.1 ± 0.02 0.16 ± 0. 4 0.12 ± 0.01 0.1 ± 0.02 0.21 ± 0.01
21 day 0.02 ± 0.02 0.25 ± 0.01 0.04*** ± 0.04 0.08** ± 0.03 0.03*** ± 0.02 0.04*** ± 0.01 0.15* ± 0. 2 0.1** ± 0.01 0.1** ± 0.03 0.15* ± 0.01
HC: healthy control, AC: arthritis control, BPA: biphenyl acetic acid, FEN: fenbufen, BP-1: chimeric derivative of BPA with L-tryptophan BP-2: chimeric derivative of BPA with L-glutamine, TP:
L-tryptophan, GLU: L-glutamine, PMT: physical mixture of BPA with L-tryptophan, PMG: physical mixture of BPA with L-glutamine.
* Average of six readings ±SEM, P< 0.05.
** Average of six readings ±SEM, P< 0.01.
*** Average of six readings ±SEM, P< 0.001.
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Figure 2 Photomicrographs of histopathological studies of rat ankle joints (stain: hematoxyline and eosine, resolution: 40X). Healthy
control (HC): normal tissue architecture, arthritis control (AC): large inﬂammation and granulation tissue around joint, biphenyl acetic
acid (BPA): large granulation tissue, eosinophilic predominance, fenbufen (FEN): large granulation tissue with ﬁbrosis, giant cell
inﬁltration, chimeric derivative with L-tryptophan (BP-1): small granulation tissue, chimeric derivative with L-glutamine (BP-2): moderate
granulation tissue, L-tryptophan (TP): large granulation tissue, mononuclear inﬁltration, L-glutamine (GLU): large granulation tissue,
mononuclear inﬁltration, physical mixture of biphenyl acetic acid and L-tryptophan (PMT): acute inﬂammatory cells with eosinophilic
predominance, physical mixture of biphenyl acetic acid and L-glutamine (PMG): acute inﬂammatory cells with eosinophilic predominance,
granulation tissue.
S216 S. Dhaneshwar et al.and at room temperature for 36 h. After ﬁltration, the ﬁltrate was
evaporated under reduced pressure to remove the solvent. The
residue obtained was washed with ethyl acetate (25 mL) and then
dissolved in methanol (15 mL) and ﬁltered. Methanol was evap-
orated under reduced pressure to obtain crude product. It was
puriﬁed by preparative TLC using solvent system methanol:ben-
zene:ethyl acetate:glacial acetic acid (1.5:0.5:0.5:0.1 v/v).
BP-2: % yield: 59, mp: 152–155 C (d; uncorrected), Rf: 0.4,
ethyl acetate:methanol:glacial acetic acid (2:1:0.1 v/v), logP:1.20 (n-octanol:phosphate buffer pH 7.4), kmax: 279 nm (phos-
phate buffer pH 7.4), IR (KBr; cm1): 3324 NH stretching sec-
ondary amide, 3201 aromatic CH stretching, 2981 NH
stretching primary amide, 1738 C‚O stretching COOH,
1649 C‚O stretching amide.1H NMR (DMSO-d6,): d 10.73
[bs, 1H] COOH, d 7 .59 [bs, 1H] NH amide, 6.94–7.45 [m,
9H] aromatic protons, d 5.78 [bs, 2H] NH2 amine, d 3.36 [s,
2H] CH2 methylene, d 3.00–3.07 [q, 2H] CH2 methylene, d
2.49–2.50 [t, 1H] CH methane, d 1.2 [t, 2H] CH2 methylene.
Reducing ulcerogenic potential of biphenyl acetic acid: Design and development S2173. Biological evaluation
The animals were procured from National Toxicological Cen-
tre, Pune for the present study. They were housed in groups of
6 in solid bottom polypropylene cages and maintained at
24 ± 1 C, with relative humidity of 45–55% and 12:12 h
dark/light cycle. Acclimatization period was 2 weeks. The ani-
mals had free access to food (standard chow pellets, Chakan
Oil Mills, Sangli) and water, ad libitum. The animal facilities
of the Department of Pharmacology at Poona College of Phar-
macy are approved by Committee for the Purpose of Control
and Supervision of Experimental Animals (Reg. No.100/1999/
CPCSEA) . The pharmacological and acute toxicity protocols
were approved by The Institutional Animal Ethics Committee
(IAEC) of Poona College of Pharmacy, Pune. For all the activ-
ities the animals were divided into various standard and test
groups. BPA and fenbufen were used as standard NSAIDs HC                             AC                           
BP-1                            BP-2                        
 PMT                      
Figure 3 Radiological evaluation of rat paws in CFA-induced arth
severe bone erosion, biphenyl acetic acid (BPA): mild bone erosion, fe
tryptophan (BP-1): mild bone erosion, chimeric derivative with L-glu
bone erosion, L-glutamine (GLU): severe bone erosion, physical mixt
erosion, physical mixture of biphenyl acetic acid and L-glutamine (PMwith which the results of prodrugs, individual carriers and
physical mixture of BPA with carriers were compared.
3.1. Animals
Albino Wistar rats of either sex (150–200 g) were used for the
screening of anti-inﬂammatory activity by carrageenan-in-
duced rat paw edema model and Freund’s adjuvant arthritis
model whereas for ulcerogenic activity, Wistar rats of either
sex (200–300 g) were used. Analgesic activity was carried out
using mice of either sex (20–30 g). The animals were distrib-
uted into control, standard and test groups, having six animals
each. The doses of BP-1 and BP-2 were calculated on an equi-
molar basis to fenbufen. The standard and the test compounds
were administered orally as a suspension in distilled water
using 1% sodium CMC. Radiological evaluation of rat paw
was performed at Bhandarkar X-ray Clinic, Pune.   BPA                          FEN 
  TP                            GLU 
               PMG 
ritis. Healthy control (HC): Normal bone, arthritis control (AC):
nbufen (FEN): moderate bone erosion, chimeric derivative with L-
tamine (BP-2): moderate bone erosion, L-tryptophan (TP): severe
ure of biphenyl acetic acid and L-tryptophan (PMT): severe bone
G): severe bone erosion.
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An average of six readings was calculated and data were ex-
pressed as mean ± SEM. Statistical differences between the
groups were calculated by One-way ANOVA followed by
Dunnett’s Multiple Comparison test for carrageenan-induced
rat paw edema, analgesic activity and ulcerogenic potential
and Two-way ANOVA followed by Bonferroni’s test for Fre-
und’s adjuvant arthritis model.3.3. Analgesic activity (Eddy and Leimbach, 1953)
The analgesic activity was carried out using hot plate method.
Mice of either sex were distributed into control, standard and
test groups, having six animals each. The paws of mice being
sensitive to heat were exposed to a temperature not damaging
to the skin and the response in the form of jumping, with-
drawal of the paws or the licking of the paws was observed.
The mice were placed on Eddy’s hot plate (equipped with a
thermostat) kept at a temperature of 55 ± 0.5 C. A cut off
period of 20 s was observed to avoid damage to the paw. Reac-
tion time and the type of response were noted using a stop-
watch. At 0 min the standard and test compounds were
administered orally in the form of suspension. The latency per-
iod was recorded at 20, 60, 90, 120 and 180 min following an
oral administration of the compounds and average reaction
times were then calculated.3.4. Anti-inﬂammatory activity (Winter et al., 1962)
Carrageenan-induced rat paw edema method was used to eval-
uate the anti-inﬂammatory activity of prodrugs on the acute
inﬂammation. At 0 h the standard and test compounds were
administered orally in the form of suspension. One hour after
this treatment, edema was induced by injecting 0.1 mL of 1%
w/v suspension of carrageenan (C-3889 Type IV, Sigma Chem-
icals, St. Louis, MO) in the sub-plantar region of the hind paw.
The control group received 1% CMC. Paw volumes were mea-
sured before and after the administration of carrageenan using
a UGO-Basile Plethysmometer 7140, Italy. The percent inhibi-
tion was calculated using the formula (1Vt/Vc) · 100, where
Vt and Vc are the mean relative changes in the paw volume in
test and control respectively.
3.5. Anti-arthritic activity (Vogel and Vogel, 1997)
Anti-arthritic activity was evaluated using Freund’s adjuvant-
induced arthritis model. On day one, 0.1 mL of complete Fre-
und’s adjuvant (CFA) (F-5881, Sigma–Aldrich Co., USA) was
injected into the sub-plantar region of the hind paw. The ani-
mals were housed in cages to allow the development of full
arthritis up to 13 days. Assessment of arthritis was done by
measuring change in joint diameter (Vernier calliper), change
in paw volume (UGO-Basile Plethysmometer 7140, Italy), %
inhibition of edema on 0th, 1st, 4th, 7th, 13th, 18th, and
21st days after Freund’s adjuvant injection. Histopathological
studies of rat ankle joint and radiological evaluation of rat paw
was also undertaken at the end of the study. On 13th day the
drug administration was started and continued up to 21st day.
The arthritic control group received 1% CMC solution. Theaverage foot swelling in standard and test groups was com-
pared with the arthritic control group and % inhibition of ede-
ma was determined by using the same formula which was used
to evaluate anti-inﬂammatory activity.
3.5.1. Histopathology and radiology of ankle joint in CFA-
induced arthritis
Histopathology of rat ankle joint was performed by Dr. Sange-
eta Kohli (M.D., Pathology) at Satyam Pathology, Pune. Sec-
tions of ankle joint were stained by hematoxyline and eosine.
Photomicrographs were taken by Nicon optical microscope
Eclipse E-200 with a resolution of 40X. Radiological evalua-
tion of rat paw was done at Bhandarkar X-ray Clinic, Pune.
3.6. Ulcerogenic potential (Rainsford and Whitehouse, 1980)
The ulcerogenic potential was evaluated by Rainsford’s cold
stress method. BPA and fenbufen were taken as standards.
The test compounds and standards were administered orally,
in 1% CMC at ten times higher doses. Following the oral
administration of drug suspensions, the animals were stressed
by exposure to cold at 15 C for 1 h. Two hours after drug
administration, the animals were sacriﬁced to remove stomach
and duodenum. They were opened by a cut along greater cur-
vature, washed with saline and then with the help of a magni-
fying lens, the number of ulcers larger than 0.5 mm was
counted. The ulcers were scored according to the scoring meth-
od of Cioli et al. (1979) and then the ulcer indices were
determined.
4. Results and discussion
Chimeric derivatives were puriﬁed by preparative TLC using
benzene:ethyl acetate:glacial acetic acid (2:1:0.1 v/v) and ethyl
acetate:methanol:glacial acetic acid (2:1:0.1 v/v) for BP-1 and
BP-2 respectively. The logP values of BP-1 and BP-2 were
found to be 0.46 and 1.2 respectively which were lower than
BPA (logP 3.21) corresponding to 2.67–6.9 times more hydro-
philic than BPA. The IR spectra of the synthesized compounds
showed –NH and C‚O stretchings characteristic for amides.
The 1H NMR spectra showed chemical shifts at d 7.95 and d
7.59 for amide proton (for BP-1 and BP-2 respectively) which
were characteristic of their anticipated structures. Thus the
spectral analysis conﬁrmed the anticipated structures.
In hot plate-induced hyperalgesia model (Table 1), BPA
and fenbufen showed the onset of analgesic activity at
60 min (latency 24.9 s) and 90 min (latency 21.6 s) respectively
while BP-1 and BP-2 although showed the onset of analgesic
activity at 60 min (latency 26.6 and 22 s respectively), it was
maintained till 120 min (latency 39.9 s) to 180 (latency 25.5 s)
respectively unlike BPA and fenbufen. Both the derivatives
exhibited quicker onset and longer duration of analgesia
(120–180 min) than fenbufen. In carrageenan induced-hind
paw edema model, paw volume was measured at different time
intervals in order to evaluate the onset and duration of action
of the chimeras (Table 2). BP-1 (47.7%) and BP-2 (54.5%)
showed late onset of the anti-inﬂammatory action at 6 and
8 h respectively. The anti-inﬂammatory activity of BP-1 was
maintained during 6–24 h. The overall extent of the inhibition
of edema (Table 3) provided by BP-1 was 1.2 times higher than
BP-2, BPA and fenbufen. BP-1 and BP-2-treated animals
Table 6 Ulcerogenic potential in the form of ulcer index.
Group aDose (mg/kg) Ulcer index ± S.D.
HC 1% CMC NIL
BPA 120 91.2 ± 0.03
FEN 150 73.2 ± 0.02
BP-1 224 12.4 ± 0.01
BP-2 192.4 19.6 ± 0.02
TP 115.5 1.4 ± 0.04
GLU 84.7 2.3 ± 0.01
HC: healthy control, BPA: biphenyl acetic acid, FEN: fenbufen,
BP-1: chimeric derivative of BPA with L-tryptophan, BP-2: chi-
meric derivative of BPA with L-glutamine, TP: Ltryptophan, GLU:
L-glutamine, PMT: physical mixture of BPA with L-tryptophan,
PMG: physical mixture of BPA with L-glutamine.
a Ten times higher dose.
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Table 5 thus offering more protection against inﬂammation
than BPA. BP-1 and BP-2 showed similar anti-arthritic activity
(Table 4) (71% and 70% respectively) which was better than
BPA (66%), fenbufen (53%), individual amino acids and phys-
ical mixtures. In histopathological studies of rat ankle joints
(Fig. 2), BP-1 showed a small granulation tissue while BP-2
showed a moderate granulation tissue indicating extensive
reduction in the severity of inﬂammation while BPA and fen-
bufen-treated animals showed large granulation with inﬂam-
matory inﬁltration indicating moderate protection. In
radiological studies of rat paws (Fig. 3) (CFA-induced arthri-
tis), BP-1 showed better protection against the bone deformity
induced in arthritis than BPA. BP-2 showed moderate bone
erosion which was comparable with fenbufen. Both chimeric
derivatives exhibited good protection against bone deformities
in arthritis.
BP-1 and BP-2 produced signiﬁcantly few ulcers as com-
pared to BPA and fenbufen (Table 6) emphasizing a predom-
inant contribution of free carboxylic group of BPA and
fenbufen in their ulcerogenic tendencies.
5. Conclusion
Treatment of inﬂammatory disorders like RA requires a fre-
quent intake of anti-inﬂammatory drugs at high doses. NSA-
IDs are associated with major GIT side effects which are
generally attributed to a direct and/or an indirect mechanism.
The direct contact effect results usually from local irritation
produced by the acidic group of NSAIDs. A possible way to
minimize the local irritant effect is the derivatization of their
carboxylic group to produce chimeric derivatives with ade-
quate stability at the acidic pH of the stomach. Using the same
approach, gastro-sparing chimeras of biphenyl acetic acid were
successfully synthesized using anti-inﬂammatory amino acids
as promoities. Conversion of a bioprecursor prodrug (fenbu-
fen) into chimeric derivatives proved to be productive in terms
of high gastro-sparing effect; quick onset and longer duration
of analgesia; enhanced/prolonged anti-inﬂammatory activity
and better anti-arthritic effect. These derivatives could be use-
ful as a chronotherapy for RA due to their prolonged analgesic
and anti-inﬂammatory effects.Acknowledgements
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